RxDoctor Payments Data

Matthew Knudson, MD

Urology · Quincy, ILNPI 1962609768

Payments from drug & device makers

$4,134in general payments, 2019–2025

Across 215 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$421
  • 180 Medical, Inc.$287
  • Convatec Inc.$278
  • Pfizer$258
  • AbbVie$202
  • plus $1K from 23 others

What the payments were for

  • Speaking & faculty fees$2586%
  • Food & beverage$3,72490%
  • Education$1293%
  • Other$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,134 in reported general payments places this provider in the 60th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$289,744
Medicare patients
647
Services billed
3,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron331$196,502
Mirabegron ErMirabegron32$19,884
Methenamine Hippurate280$15,916
Tamsulosin Hcl684$8,433
Finasteride610$7,644
Solifenacin Succinate131$5,655
Oxybutynin Chloride ErOxybutynin Chloride181$4,114
Estradiol51$3,917
Trimethoprim34$2,703
Fosfomycin Tromethamine11$2,211
Cefdinir82$2,102
NitrofurantoinNitrofurantoin Macrocrystal53$1,637
Potassium Citrate ErPotassium Citrate30$1,362
Testosterone Cypionate31$1,311
Cephalexin280$1,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$421$196,502331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 550 urology providers in Illinois.

Other urology in Quincy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →